Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Change in Receivables (2020 - 2024)

Janux Therapeutics (JANX) has disclosed Change in Receivables for 5 consecutive years, with $7.0 million as the latest value for Q2 2024.

  • Quarterly Change in Receivables rose 1030.8% to $7.0 million in Q2 2024 from the year-ago period, while the trailing twelve-month figure was $7.5 million through Jun 2025, up 11.11% year-over-year, with the annual reading at -$8.0 million for FY2021, 200.0% down from the prior year.
  • Change in Receivables for Q2 2024 was $7.0 million at Janux Therapeutics, up from $519000.0 in the prior quarter.
  • The five-year high for Change in Receivables was $8.0 million in Q4 2020, with the low at -$7.6 million in Q1 2021.
  • Average Change in Receivables over 5 years is $833333.3, with a median of $500000.0 recorded in 2022.
  • Peak annual rise in Change in Receivables hit 1030.8% in 2024, while the deepest fall reached 30.8% in 2024.
  • Over 5 years, Change in Receivables stood at $8.0 million in 2020, then plummeted by 104.69% to -$375000.0 in 2021, then plummeted by 33.33% to -$500000.0 in 2022, then tumbled by 50.0% to -$750000.0 in 2023, then skyrocketed by 1030.8% to $7.0 million in 2024.
  • According to Business Quant data, Change in Receivables over the past three periods came in at $7.0 million, $519000.0, and -$750000.0 for Q2 2024, Q1 2024, and Q2 2023 respectively.